Dose-Dependent Effect of Metformin Preconditioning on the Regenerative Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells: An In Vitro Experimental Study

In the vast landscape of regenerative medicine, scientists often look to the body's own repair crews: stem cells. These are special, versatile cells capable of turning into bone, nerve, or muscle tissue, acting as a biological toolkit for healing damaged organs. Among the most promising sources for these cells is the umbilical cord, a tissue that is usually discarded after birth. Cells harvested from the jelly-like substance inside the cord are young, easy to grow in a lab, and carry fewer ethical concerns than cells taken from adults. However, a persistent challenge remains: while these cells are plentiful, their quality can be inconsistent. When scientists try to grow them in large numbers for medical use, the cells often lose their vigor, becoming tired and less effective at their job. To solve this, researchers are exploring ways to "precondition" these cells—giving them a brief, controlled boost before they are used, much like an athlete warming up before a race. One common medication, widely used for decades to treat diabetes, has recently caught the attention of cell biologists as a potential tool for this warm-up.

A team of researchers in Pakistan set out to test whether this diabetes medication, known as metformin, could improve the performance of stem cells from the umbilical cord. They did not simply add the drug and hope for the best; instead, they treated the cells like a delicate instrument, testing a wide range of doses to find the precise amount that would help without causing harm. The study focused on a fundamental question: does a little bit of this drug help the cells grow stronger, or does too much poison them? The researchers isolated cells from the umbilical cords of ten healthy newborns and grew them in the laboratory. They then exposed these cells to different concentrations of metformin, ranging from none at all to very high doses, and watched how the cells responded over time.

The results revealed a clear and distinct pattern, showing that the effect of the drug depends entirely on the dose. When the researchers used a low dose of 100 units, the cells thrived. They grew faster, survived better, and formed more colonies than the untreated cells. This specific amount acted as a catalyst, making the cells more active and ready for their future work. In fact, the cells treated with this low dose showed a 6 percent increase in their ability to form new colonies and maintained a faster growth rate even after being divided multiple times. They also showed a greater readiness to transform into bone-forming cells and nerve-like cells, which are two of the most important jobs for these stem cells. The gene markers that signal the cells are turning into bone or nerve tissue were significantly higher in the group treated with this low dose.

However, the story changed dramatically when the dose was increased. The researchers found that the benefits disappeared as the concentration rose. When they used a high dose of 1,000 units, the cells began to struggle. Their growth slowed down, their ability to form new colonies dropped sharply, and they became less effective at changing into specialized tissue. The highest dose was actually harmful, causing the cells to grow much more slowly and lose their potential. This confirmed that metformin is not a simple "more is better" solution; it is a tool that requires precise calibration. The study demonstrated that there is a specific window where the drug helps, but stepping outside that window, even slightly, can turn a helpful agent into a hindrance.

The researchers also looked closely at how the cells changed their shape and behavior. Under the microscope, the cells treated with the optimal low dose looked healthier and more robust. When pushed to become bone cells, they built stronger mineral structures. When encouraged to become nerve-like cells, they developed longer, more defined extensions, resembling the branches of a neuron. These changes were not just visual; the genetic activity inside the cells confirmed that they were indeed shifting toward these specialized roles more effectively than the untreated cells. The study carefully noted that while the cells looked more like nerve cells, they were not fully mature neurons, but rather showed a strong response toward that direction.

This work provides a clear roadmap for how to use metformin to improve stem cells. It suggests that a low dose of 100 units is the sweet spot for enhancing the quality of umbilical cord stem cells, making them more vigorous and capable of healing. At the same time, it serves as a warning that higher doses can damage these cells, slowing their growth and reducing their usefulness. The findings are specific to the laboratory conditions tested, and the researchers emphasize that more work is needed to understand exactly how the drug works inside the cell and whether these results will hold true when used in living patients. For now, the study offers a precise, evidence-based guide: a small, measured amount of metformin can revitalize these cells, but getting the dose wrong can undo the benefits entirely.